Trial Profile
Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- 20 Jan 2017 New trial record